New Technology– category –

OncLive USA Overview The European Commission has approved the combination of pembrolizumab and enfortumab vedotin as perioperative treatment for adults with resectable muscle-invasive bladder cancer (MIBC). Data from the KEYNOTE-B15 tria...

Targeted Oncology USA Overview Sofetabart mipitecan demonstrated a 50.5% objective response rate in heavily pretreated high-grade ovarian cancer patients, regardless of FRα expression levels. The study identified 3 mg/kg as the recommend...

Indiana University School of Medicine USA Overview Researchers at the Indiana University School of Medicine have developed molecular glue degrader compounds that reduce the formation of amyloid plaques by targeting amyloid precursor prot...

ScienceDaily / University of Wisconsin-Madison USA Overview The FDA has approved Zanvastro, the first disease-modifying drug for Alexander disease, a rare neurological disorder affecting fewer than one in a million people. Developed thro...

UVA Health USA Overview Researchers have developed a novel method to identify multitarget miRNAs that inhibit glioblastoma growth by targeting multiple cancer-promoting pathways simultaneously. By combining nanoparticles with microbubble...

The Stanford Daily USA Overview Stanford researchers developed Virtual Biotech, an AI-powered platform that can reduce drug discovery timelines from months to days. By emulating a full R&D organization with tens of thousands of AI ag...

CancerNetwork USA Overview The FDA has approved atezolizumab in combination with chemotherapy for the adjuvant treatment of patients with resected stage III mismatch repair deficient (dMMR) colon cancer. Based on the phase 3 ATOMIC trial...

arXiv (Preprint) Sweden Overview RetroTAC is a machine-learning surrogate model that predicts the synthetic accessibility of Proteolysis-targeting chimeras (PROTACs) based on route-derived scores. The ensemble model achieves a root mean ...

Voumed USA Overview Retatrutide, a triple-hormone receptor agonist developed by Eli Lilly, demonstrated mean weight reductions of 26% to 28% in Phase 3 trials. The compound targets GIP, GLP-1, and glucagon receptors to enhance energy exp...

PR Newswire (Insilico Medicine) USA Overview Insilico Medicine has nominated ISM9546, an oral, peripherally restricted VAV1 molecular glue degrader, as a preclinical candidate (PCC) for autoimmune diseases such as IBD and RA. The candida...